CONMED Corporation (CNMD) — Fair Value Analysis

Base-case fair value (P50): $30.19 · Current price: $32.44 · Verdict: Fairly Valued

The Verdict on CNMD

CONMED CORP (CNMD) currently trades at $32.44, with our Monte Carlo simulations indicating a median fair value (P50) of $30.19. This implies a -6.9% against the current market price, leading to our assessment that CNMD is Fairly Valued. While the Monte Carlo model explores thousands of forward scenarios to determine a comprehensive valuation range, the close proximity of $32.44 to the $30.19 fair value suggests the market has largely priced in the company's fundamentals, mitigating immediate concerns of significant overvaluation or undervaluation.

How CNMD stacks up against peers

Our analysis places CNMD in an average quality tier, reflecting its operational and financial health relative to the broader sector. This average standing informs the inputs to our Monte Carlo simulations, shaping the probability distributions for various valuation drivers. Despite an average quality rating, the Fairly Valued verdict, derived from a -6.9% difference between $32.44 and $30.19, indicates that its intrinsic strengths and weaknesses are broadly reflected in the current market price. This suggests CNMD is neither excessively expensive nor remarkably cheap compared to its peer set at $32.44.

What this means for investors

For investors considering CNMD, the Fairly Valued assessment, based on a median fair value (P50) of $30.19 against the current $32.44, suggests a balanced risk-reward profile. The -6.9% indicates limited immediate alpha potential from a pure valuation perspective at these levels. Our Monte Carlo framework, encompassing various future scenarios, suggests the current price does not present a compelling overvaluation that would warrant an immediate negative outlook. For a deeper dive into the full bear and bull case distribution, sign up for FairCurve to track CNMD's fair value as new fundamentals are released.